Hikma Pharmaceuticals (OTCMKTS:HKMPF) Sets New 1-Year Low - Time to Sell?

Key Points

• Hikma Pharmaceuticals shares hit a new 52-week low at $22.00 during trading, down from a previous close of $22.37.
• The company has a **debt-to-equity ratio** of 0.33 and a **current ratio** of 1.24, indicating a manageable debt level and adequate liquidity.
• Hikma Pharmaceuticals primarily develops and markets **generic, branded, and in-licensed pharmaceutical products** through its segments: Injectables, Generics, and Branded.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report)'s stock price hit a new 52-week low on Friday . The company traded as low as $22.00 and last traded at $22.00, with a volume of 225 shares traded. The stock had previously closed at $22.37.

Hikma Pharmaceuticals Trading Up 3.4%

The company has a current ratio of 1.24, a quick ratio of 0.72 and a debt-to-equity ratio of 0.33. The business has a 50-day moving average price of $25.14 and a two-hundred day moving average price of $26.32.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.